The dose of IFNα-Le used in both the rat and mouse model was slightly higher than the dose chosen for a cutaneous melanoma study (Stadler et al. 2006), but is in line with the current practice for IFNα-2b treatment of chronic myeloid leukemia and chronic hepatitis B (Online Resources). Here, IFNA1 is linked to chronic hepatitis B virus infection.